Welcome to our dedicated page for China Pharma news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma stock.
China Pharma Holdings, Inc. (NYSE American: CPHI) generates news across pharmaceuticals, medical devices, financing, and corporate actions. As a specialty pharmaceutical company focused on cardiovascular, CNS, infectious, and digestive diseases in China, its announcements often relate to product development milestones, regulatory progress, and changes in its capital structure.
News updates have covered the company’s reverse stock splits, including 1-for-10 and 1-for-5 ratios, as well as stockholder authorization for a potential reverse split of up to 1:20. These items are relevant for investors tracking share structure and listing status on the NYSE American. Company press releases also describe financing arrangements such as a Convertible Promissory Note and an at-the-market equity offering under a shelf registration statement on Form S-3.
Operational and product-related news includes the launch of an N95 medical protective mask, the listing of several drugs in the Catalogue of Medicines for People Infected with COVID-19, and regulatory milestones for key products. For example, the company has reported that its candesartan hypertension product passed the quality and efficacy consistency evaluation of generic drugs by the National Medical Products Administration of China. It has also provided updates on its Dry Eye Disease therapeutic device, including completion of third-party testing and expectations around market launch applications.
In addition, China Pharma issues news on technology transfer agreements for patented pharmaceutical inventions, such as ipragliflozin tablets and captopril microcapsules, where consideration is paid in restricted shares of common stock. Readers of the CPHI news page can review these developments to follow how the company manages its product pipeline, regulatory interactions, financing strategies, and corporate governance decisions over time.
China Pharma Holdings, Inc. (NYSE American: CPHI) reported a 33.7% increase in revenue to $2.4 million for Q1 2021, up from $1.8 million a year earlier, primarily due to recovery from COVID-19 and favorable exchange rates. The company achieved a gross margin of 11.6%, slightly up from 11.0% in Q1 2020. However, the net loss widened to $0.8 million due to increased R&D investments. The company's CEO highlighted optimism for growth driven by a diversified product portfolio and upcoming product launches in compliance with Hainan Free Trade Port policies.
China Pharma Holdings, Inc. (CPHI) has responded to new policy measures supporting the Hainan Free Trade Port. These measures include the establishment of an e-prescription center and increased access for market drugs, expected to stimulate company growth. On April 17, 2021, they signed an agreement with Huiyi, an Internet hospital with over 40,000 registered doctors, to leverage the policy changes. The reforms also aim to attract investment and enhance medical tourism, projecting significant financial benefits for China Pharma, with potential market access worth up to 100 billion yuan by 2022.
China Pharma Holdings, Inc. (CPHI) reported fiscal year 2020 results with revenue of $10.9 million, unchanged from 2019. The gross margin improved to 18.0% from 13.6%, while loss from operations decreased significantly to $2.6 million versus $20.4 million in 2019. Net loss also improved to $2.9 million, equating to $0.07 per share. The company highlights a one-time revenue boost from COVID-19 testers totaling $1.7 million. Despite challenges, particularly from the pandemic, China Pharma aims to bolster healthcare product development and maintain financial sustainability.
China Pharma Holdings, Inc. (CPHI) announced its Q3 2020 financial results, reporting revenue of $2.4 million, unchanged from Q3 2019. Gross margin plunged to 2.0% from 15.7% year-over-year, with a net loss of $1.0 million compared to $0.7 million in the prior year. The operational loss also increased to $1.0 million. For the nine months ending September 30, 2020, total revenue stayed at $7.9 million, with a reduced net loss of $1.7 million versus $2.0 million in 2019. The decrease in net loss was aided by a foreign trade deal involving COVID-19 testers.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced that its subsidiary, Hainan Helpson Medicine & Biotechniqe Co., Ltd., has received multiple certifications for its masks. These include the Disposable Medical Mask, Particle Filtering Half Mask, and KN95 Particulate Respirator, all meeting international filtration standards. The masks, produced in GMP-certified facilities, are now available for sale on the e-commerce platform 1688.com. This initiative supports global COVID-19 prevention efforts by providing high-quality masks to various markets.
China Pharma Holdings, Inc. (CPHI) reported a 46.8% revenue increase to $3.8 million for Q2 2020, driven primarily by a one-time sale of COVID-19 testers contributing $1.7 million. Gross margin improved to 30.5% from 6.4% year-over-year, while the company achieved an operating income of $0.1 million, compared to a loss of $0.8 million in the same quarter of 2019. Despite positive growth, net income was minimal at $0.01 million, as prior drug sales were affected by the COVID-19 outbreak. Cash and equivalents stood at $1.8 million, up from $1.1 million.
China Pharmaceutical Holdings Limited (NYSE American: CPHI) will hold its Q2 2020 earnings conference call on August 14, 2020, at 8:30 a.m. ET. Participants must register in advance to receive dial-in details. The call will provide insights into the company's financial performance and strategic direction. A replay will be available until August 22, 2020. China Pharma focuses on specialty pharmaceuticals in China, targeting high-incidence conditions such as cardiovascular and infectious diseases, supported by a nationwide distribution network.